Versant Venture Capital Vii, L.p. - Net Worth and Insider Trading
Versant Venture Capital Vii, L.p. Net Worth
The estimated net worth of Versant Venture Capital Vii, L.p. is at least $284 Million dollars as of 2024-11-05. Versant Venture Capital Vii, L.p. is the 10% Owner of Chinook Therapeutics Inc and owns about 7,038,369 shares of Chinook Therapeutics Inc (KDNY) stock worth over $284 Million. Details can be seen in Versant Venture Capital Vii, L.p.'s Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Versant Venture Capital Vii, L.p. has not made any transactions after 2021-08-27 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Versant Venture Capital Vii, L.p.
Versant Venture Capital Vii, L.p. Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Versant Venture Capital Vii, L.p. owns 3 companies in total, including Aduro Biotech Inc (ADRO) , Chinook Therapeutics Inc (KDNY) , and RayzeBio inc (RYZB) .
Insider Ownership Summary of Versant Venture Capital Vii, L.p.
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| ADRO | Aduro Biotech Inc | 2020-10-05 | 10 percent owner |
| KDNY | Chinook Therapeutics Inc | 2021-08-27 | 10 percent owner |
| RYZB | RayzeBio inc | 2023-09-14 | 10 percent owner |
Versant Venture Capital Vii, L.p. Latest Holdings Summary
Versant Venture Capital Vii, L.p. currently owns a total of 1 stock. Versant Venture Capital Vii, L.p. owns 7,038,369 shares of Chinook Therapeutics Inc (KDNY) as of August 27, 2021, with a value of $284 Million.
Latest Holdings of Versant Venture Capital Vii, L.p.
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| KDNY | Chinook Therapeutics Inc | 2021-08-27 | 7,038,369 | 40.39 | 284,279,724 |
Holding Weightings of Versant Venture Capital Vii, L.p.
Versant Venture Capital Vii, L.p. Form 4 Trading Tracker
According to the SEC Form 4 filings, Versant Venture Capital Vii, L.p. has made a total of 1 transactions in Chinook Therapeutics Inc (KDNY) over the past 5 years, including 0 buys and 1 sells. The most-recent trade in Chinook Therapeutics Inc is the sale of 850,000 shares on August 27, 2021, which brought Versant Venture Capital Vii, L.p. around $12 Million.
Insider Trading History of Versant Venture Capital Vii, L.p.
- 1
Versant Venture Capital Vii, L.p. Trading Performance
Versant Venture Capital Vii, L.p. Ownership Network
Ownership Network List of Versant Venture Capital Vii, L.p.
Ownership Network Relation of Versant Venture Capital Vii, L.p.
Versant Venture Capital Vii, L.p. Owned Company Details
What does Aduro Biotech Inc do?
Who are the key executives at Aduro Biotech Inc?
Versant Venture Capital Vii, L.p. is the 10 percent owner of Aduro Biotech Inc. Other key executives at Aduro Biotech Inc include director & President & CEO Eric Dobmeier , 10 percent owner Versant Voyageurs I, L.p. , and 10 percent owner Versant Voyageurs I Parallel, L.p. .
Aduro Biotech Inc (ADRO) Insider Trades Summary
In summary, during the past 3 months, insiders sold 0 shares of Aduro Biotech Inc (ADRO) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Aduro Biotech Inc (ADRO) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.
Aduro Biotech Inc (ADRO)'s detailed insider trading history can be found in Insider Trading Tracker table.
Aduro Biotech Inc Insider Transactions
Versant Venture Capital Vii, L.p. Mailing Address
Above is the net worth, insider trading, and ownership report for Versant Venture Capital Vii, L.p.. You might contact Versant Venture Capital Vii, L.p. via mailing address: One Sansome Street, Suite 1650, San Francisco Ca 94104.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
